Meridian Bioscience Announces the Launch of a High-Sensitivity SARS-CoV-2 Nucleocapsid Antibody Pair for the Development of Rapid COVID-19 Antigen Assays

CINCINNATI, July 13, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading provider of diagnostic testing solutions and life science raw materials, announced today that it has launched a high-sensitivity SARS-CoV-2 nucleocapsid antibody pair for the development of rapid COVID-19 antigen assays.
Since the emergence of COVID-19 in January, Meridian has worked side-by-side with molecular diagnostic companies with critical master mixes and enzymes for their COVID-19 molecular diagnostics tests.A  These tests are typically ultra-sensitive and can diagnose early in the infection, but they must be carried out by trained technicians in a laboratory, delaying diagnosis.A  To meet the critical need for easier, faster and cheaper screening assays, Meridian has launched a highly sensitive and specific pair of monoclonal antibodies that are ideal for developing reliable and sensitive rapid lateral flow antigen assays for the detection of active COVID-19 infections.A a??There are many highly sensitive molecular tests available that can diagnose an infection early, but they require processing in a laboratory and take time to report a result.A  We now provide an antibody pair that can be used to create fast, point-of-care assays, capable of delivering results in minutes rather than hours,a?? commented Lourdes Weltzien, Ph.D., Executive Vice President, Life Science. A a??Although a negative result does not rule out an infection, antigen tests can be a first-line screen to help determine if people are infectious, allowing much faster response to potential outbreaks.a??A Dr. Todd Howren, Vice President, Global Sales - Life Science, added, a??Since the start of this pandemic, the world has been on the defensive, reacting to the outbreak. A With the launch of this antibody pair that can detect as low as 3ng/mL of nucleocapsid in a patient sample and does not cross react with other coronaviruses (except SARS 2003), there is potential to create COVID-19 tests that can be carried out at a point-of-care setting in local communities allowing for more rigorous control.a??Meridian is committed to suppling innovative solutions to the diagnostic industry during times of a pandemic health crisis.A  For more information on partnering with Meridian Bioscience, please visit or email
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Август 2020    »